Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about APHINITY
Principal Investigator
Related Studies
Impact of COVID-19 on Cancer Care Management
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS
Dana Farber 13-09-259 DCIS Registry
Investigator: Kristie A. Bobolis, M.D.